Cover Image

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database

Aims: We aimed to estimate the risk of drug-induced liver injury (DILI) from various antifungal treatments with azoles and echinocandins causing in real-world practice.Methods: We performed disproportionality and Bayesian analyses based on data from the first quarter in 2004 to the third quarter in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhi-Xuan Zhou (Author), Xue-Dong Yin (Author), Yu Zhang (Author), Qi-Hui Shao (Author), Xin-Yu Mao (Author), Wen-Juan Hu (Author), Yun-Lin Shen (Author), Bin Zhao (Author), Zhi-Ling Li (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Stevens-Johnson Syndrome Following Non-steroidal Anti-inflammatory Drugs: A Real-World Analysis of Post-marketing Surveillance Data
by: Qi-hui Shao, et al.
Published: (2022)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022)

Kidney Injury Following Ibuprofen and Acetaminophen: A Real-World Analysis of Post-Marketing Surveillance Data
by: Qi-hui Shao, et al.
Published: (2021)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
by: Shuang Zhou, et al.
Published: (2022)

Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database
by: Jinhua Chen, et al.
Published: (2024)

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
by: KaiLi Mao, et al.
Published: (2024)

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System
by: Mengling Ouyang, et al.
Published: (2024)

Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database
by: Geliang Liu, et al.
Published: (2024)

Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
by: Maoxia Fan, et al.
Published: (2024)

A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database
by: Yuan Liu, et al.
Published: (2024)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023)

Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
by: Xuan-Yi Ye, et al.
Published: (2017)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
by: Xue-Feng Jiao, et al.
Published: (2023)

Exosomes: potential diagnostic markers and drug carriers for adenomyosis
by: Wen-Xiu Cheng, et al.
Published: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database
by: Yichun Shuai, et al.
Published: (2024)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024)

Puerarin: a hepatoprotective drug from bench to bedside
by: Yi-Xiang He, et al.
Published: (2024)

Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023)

Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System（FAERS）
by: Zicheng Yu, et al.
Published: (2022)

Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system
by: Sha Zhang, et al.
Published: (2024)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023)

Evolution of anti-malaria policies and measures in P.R. China for achieving and sustaining malaria-free
by: Jian-Hai Yin, et al.
Published: (2023)

Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system
by: Wenwen Li, et al.
Published: (2024)

Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
by: Eugene Jeong, et al.
Published: (2022)

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database
by: Feng Liu, et al.
Published: (2024)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
by: Wei Wang, et al.
Published: (2023)

Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms
by: Payal Rana, et al.
Published: (2021)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2023)

Research Progress of Pharmacogenomics in Drug-Induced Liver Injury
by: Qihui Shao, et al.
Published: (2021)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022)

Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
by: Ruixue Liu, et al.
Published: (2024)

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
by: Yanjing Zhang, et al.
Published: (2024)

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases
by: Mengmeng Peng, et al.
Published: (2024)

Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
by: Hasan Afzaal, et al.
Published: (2022)

Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups
by: Xin Guan, et al.
Published: (2024)

Protective effect of hypoxia inducible factor-1α gene therapy using recombinant adenovirus in cerebral ischaemia-reperfusion injuries in rats
by: Ya-Qi Li, et al.
Published: (2020)